Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan.
Adult
Head and neck
Para-meningeal
Rhabdomyosarcoma
Salvage
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
31 Oct 2023
31 Oct 2023
Historique:
received:
05
08
2023
accepted:
15
10
2023
medline:
2
11
2023
pubmed:
31
10
2023
entrez:
31
10
2023
Statut:
epublish
Résumé
Rhabdomyosarcoma is the most common soft tissue sarcoma in children, but rare in adults. Para-meningeal rhabdomyosarcoma in head and neck (PM-HNRMS) is less applicable for surgery due to the anatomic reason. PM-HNRMS has a poor prognosis in children. However, its clinical outcomes remain unclear in adults due to the rarity. Further, there is almost no detailed data about salvage therapy. We retrospectively examined the adult patients with PM-HNRMS treated at institutions belonging to the Kyushu Medical Oncology Group from 2009 to 2022. We evaluated the overall survival (OS) and progression-free survival (PFS) of the patients who received a first-line therapy. We also reviewed the clinical outcomes of patients who progressed against a first-line therapy and received salvage therapy. Total 11 patients of PM-HNRMS received a first-line therapy. The characteristics were as follows: median age: 38 years (range 25 - 63 years), histology (alveolar/spindle): 10/1, and risk group (intermediate/high): 7/4. As a first-line therapy, VAC and ARST0431-based regimen was performed in 10 and 1 patients, respectively. During a first-line therapy, definitive radiation for all lesions were performed in seven patients. The median PFS was 14.2 months (95%CI: 6.0 - 25.8 months): 17.1 months (95%CI: 6.0 - not reached (NR)) for patients with stage I-III and 8.5 months (95%CI: 5.2 - 25.8 months) for patients with stage IV. The 1-year and 3-year PFS rates were 54.5% and 11.3% for all patients. Median OS in all patients was 40.8 months (95%CI: 12.1 months-NR): 40.8 months (95%CI: 12.1 - NR) for patients with stage I-III and NR for patients with stage IV. The 5-year OS rate was 48.5% for all patients. Among seven patients who received salvage therapy, three are still alive, two of whom remain disease-free for over 4 years after completion of the last therapy. Those two patients received multi-modal therapy including local therapy for all detected lesions. The cure rate of adult PM-HNRMS is low in spite of a first-line therapy in this study. Salvage therapy might prolong the survival in patients who received the multi-modal therapy including local therapy for all detected lesions.
Sections du résumé
BACKGROUND
BACKGROUND
Rhabdomyosarcoma is the most common soft tissue sarcoma in children, but rare in adults. Para-meningeal rhabdomyosarcoma in head and neck (PM-HNRMS) is less applicable for surgery due to the anatomic reason. PM-HNRMS has a poor prognosis in children. However, its clinical outcomes remain unclear in adults due to the rarity. Further, there is almost no detailed data about salvage therapy.
METHODS
METHODS
We retrospectively examined the adult patients with PM-HNRMS treated at institutions belonging to the Kyushu Medical Oncology Group from 2009 to 2022. We evaluated the overall survival (OS) and progression-free survival (PFS) of the patients who received a first-line therapy. We also reviewed the clinical outcomes of patients who progressed against a first-line therapy and received salvage therapy.
RESULTS
RESULTS
Total 11 patients of PM-HNRMS received a first-line therapy. The characteristics were as follows: median age: 38 years (range 25 - 63 years), histology (alveolar/spindle): 10/1, and risk group (intermediate/high): 7/4. As a first-line therapy, VAC and ARST0431-based regimen was performed in 10 and 1 patients, respectively. During a first-line therapy, definitive radiation for all lesions were performed in seven patients. The median PFS was 14.2 months (95%CI: 6.0 - 25.8 months): 17.1 months (95%CI: 6.0 - not reached (NR)) for patients with stage I-III and 8.5 months (95%CI: 5.2 - 25.8 months) for patients with stage IV. The 1-year and 3-year PFS rates were 54.5% and 11.3% for all patients. Median OS in all patients was 40.8 months (95%CI: 12.1 months-NR): 40.8 months (95%CI: 12.1 - NR) for patients with stage I-III and NR for patients with stage IV. The 5-year OS rate was 48.5% for all patients. Among seven patients who received salvage therapy, three are still alive, two of whom remain disease-free for over 4 years after completion of the last therapy. Those two patients received multi-modal therapy including local therapy for all detected lesions.
CONCLUSION
CONCLUSIONS
The cure rate of adult PM-HNRMS is low in spite of a first-line therapy in this study. Salvage therapy might prolong the survival in patients who received the multi-modal therapy including local therapy for all detected lesions.
Identifiants
pubmed: 37904096
doi: 10.1186/s12885-023-11528-4
pii: 10.1186/s12885-023-11528-4
pmc: PMC10617040
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1046Informations de copyright
© 2023. The Author(s).
Références
Ann Oncol. 2014 Jan;25(1):231-6
pubmed: 24356633
Nat Genet. 2019 Dec;51(12):1714-1722
pubmed: 31784732
Pediatr Blood Cancer. 2013 Aug;60(8):1267-73
pubmed: 23418028
Mod Pathol. 2016 Dec;29(12):1532-1540
pubmed: 27562493
Pediatr Blood Cancer. 2005 Apr;44(4):338-47
pubmed: 15503297
JCI Insight. 2022 Dec 8;7(23):
pubmed: 36282590
J Clin Oncol. 2012 Jul 10;30(20):2457-65
pubmed: 22665534
J Clin Med. 2021 Feb 17;10(4):
pubmed: 33671214
Med Oncol. 2019 May 18;36(7):59
pubmed: 31104202
J Clin Oncol. 2010 Oct 20;28(30):4658-63
pubmed: 20837952
J Clin Oncol. 2008 May 10;26(14):2384-9
pubmed: 18467730
Otolaryngol Head Neck Surg. 2011 Dec;145(6):967-73
pubmed: 21873599
Int J Mol Sci. 2022 Mar 25;23(7):
pubmed: 35408939
Eur J Cancer. 2022 Sep;172:367-386
pubmed: 35839732
J Clin Oncol. 2021 Sep 10;39(26):2859-2871
pubmed: 34166060
J Clin Oncol. 2009 Nov 1;27(31):5182-8
pubmed: 19770373
J Clin Oncol. 2012 May 10;30(14):1670-7
pubmed: 22454413
J Clin Oncol. 2016 Jan 10;34(2):117-22
pubmed: 26503200
Pediatr Blood Cancer. 2023 May 26;:e30436
pubmed: 37243336
J Clin Oncol. 2009 Jul 10;27(20):3391-7
pubmed: 19398574
J Clin Oncol. 1999 Nov;17(11):3487-93
pubmed: 10550146
PLoS One. 2011 Feb 23;6(2):e17127
pubmed: 21373200
Cochrane Database Syst Rev. 2010 Dec 08;(12):CD006669
pubmed: 21154373
J Clin Oncol. 2019 Nov 1;37(31):2866-2874
pubmed: 31513481
Front Oncol. 2023 Aug 18;13:1244035
pubmed: 37664028
Pediatr Blood Cancer. 2011 Dec 15;57(7):1261-5
pubmed: 21826783
Cancer Med. 2013 Aug;2(4):553-63
pubmed: 24156028
J Clin Oncol. 2002 Jun 1;20(11):2672-9
pubmed: 12039929
Cancer Discov. 2014 Feb;4(2):216-31
pubmed: 24436047
Otolaryngol Head Neck Surg. 2017 Jul;157(1):135-141
pubmed: 28669309
Eur J Cancer. 2021 Jul;151:84-93
pubmed: 33971448
Cancer Chemother Pharmacol. 2012 Sep;70(3):391-7
pubmed: 22806306
Clin Oncol (R Coll Radiol). 2020 Jan;32(1):e27-e35
pubmed: 31350181
Histopathology. 2022 Jan;80(1):98-108
pubmed: 34958505
Asia Pac J Clin Oncol. 2020 Apr;16(2):e47-e52
pubmed: 31657883
Cancer. 2003 Aug 1;98(3):571-80
pubmed: 12879475
J Pathol. 2014 Feb;232(3):300-7
pubmed: 24272621
Cancer Med. 2018 Aug;7(8):4023-4035
pubmed: 29956493